Vaccine Design and Delivery
One of the primary goals of the Vaccine Design and Delivery Group is to gain new fundamental knowledge that can facilitate the design, optimization and development of novel delivery systems capable of delivering loaded biopharmaceuticals to the intended target site(s). Vaccine Design and Delivery Group addresses the complex challenges associated with the formulation and targeted delivery of vaccines and nucleic acid-based therapeutics.
The research focus of the Vaccine Design and Delivery Group is advanced drug delivery. The group uses in vivo imaging (e.g., NIR, MRI and SPECT/CT) to guide and optimize the design of new nanoparticle-based delivery systems for vaccines and nucleic acid-based therapeutics to improve therapy. The research in the group is highly interdisciplinary. The team comprises 12 international researchers of various backgrounds, including pharmacists, biologists, biochemists, physicists and biotechnologists.
“Biopharmaceuticals like vaccines and nucleic acid-based therapeutics are challenging from a pharmaceutical perspective, because they are highly complex products, which can only be understood via solid fundamental science. Using systematic knowledge-based quality-by-design approaches, combined with advanced physicochemical and biopharmaceutical assessment, and molecular imaging, we design new delivery systems for biopharmaceuticals to optimize their stability, efficacy and safety” says Professor and Group Leader, Camilla Foged.
The overall research goal is to improve disease prevention and treatment in the fields of infectious and inflammatory diseases, and cancer. The group is addressing drug delivery challenges from bench-to-bedside, via international collaborations, using state-of-the-art technologies. This has fostered innovative solutions and high-impact publications in drug delivery.
Schmidt, S.T., Pedersen, G.K., Neustrup, M.A., Korsholm, K.S., Rades, T., Andersen, P., *Foged, C. and Christensen, D. (2018): Induction of cytotoxic T-lymphocyte responses upon subcutaneous administration of a subunit vaccine adjuvanted with an emulsion containing the TLR3 ligand poly(I:C), Frontiers in Immunology.
We have designed an emulsion adjuvant for vaccines that induces cytotoxic T-cell (CTL) responses. This adjuvant offers interesting perspectives, since CTL responses are essential for preventing/treating intracellular infections and cancers.
Rose, F., Wern, J.E, Gavins, F., Andersen, P., Follmann, F. and *Foged, C. (2018): A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522, J. Controlled Release 271, 88-97.
Here we report that mucosal administration of a chlamydia vaccine adjuvanted with chitosan-coated lipid-polymer nanoparticles induces mucosal vaccine responses, which are highly attractive for the immunological protection against pathogen entry directly at the site of infection.
de Groot, A.M., Thanki, K., Gangloff, M., Falkenberg, E., Zeng, X., van Bijnen, D.C.J., van Eden, W., Franzyk, H., Nielsen, H.M., Broere, F., Gay, N.J., *Foged, C. and Sijts, A.J.A.M.* (2018): Immunogenicity Testing of Lipidoids In Vitro and In Silico: Modulating Lipidoid-Mediated TLR4 Activation by Nanoparticle Design, Molecular Therapy – Nucleic Acids,
We demonstrate that the nanoparticle architecture influences the immunostimulatory properties of a nanoparticulate siRNA delivery system. Hence, immune activation during siRNA delivery may be modulated via optimization of formulation design.
Staff at Vaccine Design and Delivery
Group Leader: Camilla Foged